Table 4.

Characteristics of Patients With HoFH Stratified Based on the Presence or Absence of CAD

	With CAD (n = 139)	Without CAD (n = 59)	P Value
Male	71 (51)	15 (25)	0.002
Age at assessments, y	58 ± 13	46 ± 15	<0.001
Body mass index, kg/m2	24.5 ± 4.2	24.1 ± 5.2	0.62
Systolic blood pressure, mm Hg	126 ± 16	122 ± 16	0.19
Diastolic blood pressure, mm Hg	71 ± 13	69 ± 11	0.23
Heart rate, beats/min	71 ± 12	73 ± 10	0.40
Family history	107 (90)	54 (100)	0.04
Age at diagnosis, y	32.0 (5.8-49.0)	18.0 (4.5-37.0)	0.19
Cutaneous xanthoma	86 (62)	25 (44)	0.03
Tendon xanthoma	113 (81)	45 (78)	0.69
Achilles tendon thickness, mm	17.7 ± 7.7	17.4 ± 13.7	0.86
Achilles tendon thickness ≥9 mm	99 (99)	39 (93)	0.14
Valvular disease	40 (29)	9 (15)	0.07
Aortic valvular disease	29 (73)	5 (56)
Prior PCI	84 (62)	0 (0)	<0.001
Prior CABG	39 (31)	0 (0)	0.07
Carotid arteriosclerosis	80 (61)	25 (43)	0.03
Arcus corneae	46 (36)	13 (22)	0.08
Total cholesterol before medication, mmol/L	12.51 ± 2.49	12.03 ± 2.60	0.31
Triglycerides before medication, mmol/L	2.14 ± 1.49	1.45 ± 0.78	0.008
HDL cholesterol before medication, mmol/L	1.25 ± 0.30	1.72 ± 1.77	0.02
LDL cholesterol before medication, mmol/L	10.34 ± 2.50	9.73 ± 1.86	0.16
Genetic testing	52 (38)	12 (21)	0.03
Diagnosis			0.23
Definite	44 (32)	13 (22)
Probable	95 (68)	46 (78)
Lipoprotein apheresis	31 (23)	11 (19)	0.71
Statin	132 (96)	57 (97)	1.00
High-intensity statina	101 (73)	44 (75)	0.92
Ezetimibe	95 (68)	42 (74)	0.57
PCSK9 inhibitors	74 (53)	24 (41)	0.14

Values are n (%), mean ± SD, or mean (IQR) unless otherwise indicated.

Abbreviations as in Table 1.

^aIn this study, statin doses ≥20 mg atorvastatin, 4 mg pitavastatin, or 10 mg rosuvastatin were considered as high-intensity statin therapy.